Kin Meds Review
Best for: patients who want both compounded and brand-name GLP-1 options on one platform with publicly-disclosed pricing, plus a multi-modality longevity stack — willing to verify the actual brand-name dispensing pathway during intake (whether $149 reflects commercial insurance + manufacturer savings card or a different mechanism)
Kin Meds (kinmeds.com) is a LegitScript-verified telehealth platform offering BOTH compounded GLP-1s (Personalized GLP-1 / semaglutide $199/mo, Personalized GLP-1+GIP / tirzepatide $249/mo) AND brand-name FDA-approved options (Wegovy injection + pill, Zepbound, Foundayo at $149/mo entry). Multi-modality menu includes Sermorelin, NAD+, Glutathione, TRT, hair growth, skin health, and sexual health. Verbatim regulatory disclosure: 'Medication is compounded and dispensed by a licensed third-party pharmacy. Kin Meds is not a state-licensed pharmacy nor a drug manufacturer.'
Medium confidence · Last verified 2026-05-09 via manual · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Kin Meds is a solid telehealth option with balanced features and pricing.
Score Breakdown
Drugs Offered
Kin Meds prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Personalized GLP-1 (compounded semaglutide, starting) | compounded | $199 |
| Personalized GLP-1/GIP (compounded tirzepatide, starting) | compounded | $249 |
| Brand-name Wegovy / Zepbound / Foundayo (entry pricing) | brand | $149 |
✓ Pros
- •$199/mo compounded semaglutide and $249/mo compounded tirzepatide are publicly disclosed (uncommon pricing transparency)
- •Brand-name medications offered alongside compounded — Wegovy injection + pill, Zepbound, Foundayo all listed at $149/mo entry pricing (likely the manufacturer copay-card price for commercially insured patients)
- •LegitScript verification seal displayed
- •Verbatim regulatory disclosure clearly identifies Kin Meds as the telehealth/intake platform and the 'licensed third-party pharmacy' as the dispenser — material YMYL transparency
- •Multi-modality longevity menu (Sermorelin, NAD+, Glutathione) plus TRT + hair + skin + sexual health for cross-product retention
- •Telehealth flow (questionnaire → provider review → tailored plan → ongoing support) clearly disclosed
✗ Cons
- •Specific legal entity name + state of incorporation NOT publicly disclosed
- •Specific 'licensed third-party pharmacy' partner NOT named (verbatim disclosure acknowledges Kin Meds is NOT itself a state-licensed pharmacy)
- •Per-state availability NOT enumerated
- •$149/mo brand-name pricing for Wegovy/Zepbound/Foundayo is the entry tier — typical floors are commercial-insurance-with-savings-card; cash-pay patients should expect higher real-world costs (NovoCare $299 sema, LillyDirect $299-$449 tirz)
- •First-month promotional pricing NOT disclosed
- •Lab work + dose-titration support NOT clearly disclosed in marketing copy
- •Multi-product breadth (8+ categories) signals broad DTC telehealth rather than GLP-1-specialist platform
Ready to start with Kin Meds?
Starting at $149/month. See current pricing and start your free consultation.
Sources & methodology
Our Kin Meds review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of May 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to Kin Meds
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Ready to start with Kin Meds?
Starting at $149/month. See current pricing and start your free consultation.